Introduction
Ketolides are new semi-synthetic 14-membered ring macrolides characterized by a 3-keto group instead of an L-cladinose at position 3 on the erythronolide A ring; like erythromycin A, they inhibit protein synthesis, but the two types of compound act at different sites on the bacterial ribosome. 1 HMR 3004 (RU 64004) has shown activity against a variety of Gram-positive organisms, including erythromycin A-resistant strains. [2] [3] [4] [5] In the present study we examined the in-vitro activity of the ketolide against 161 strains of Corynebacterium spp., including isolates resistant to 14-and 16-membered-ring macrolides and lincomycin.
Materials and methods
A total of 161 clinical isolates of Corynebacterium spp. were examined including ones that were resistant to erythromycin A, josamycin and lincomycin (see Table) . HMR 3004 (RU 64004) was obtained from Hoechst Marion Roussel (Romainville, Paris, France) and erythromycin A from Pierrel (Milan, Italy). To determine crosssusceptibility, the in-vitro activity of josamycin (ICN Biomedicals, Inc, Aurora, OH, USA) and of lincomycin (Fluke Chemie AG, Buchs, Switzerland) was also studied. The MICs were determined by a standard agar dilution 
Results and discussion
Results of the MIC testing are presented as a box plot in the Figure. HMR 3004 was active against all Corynebacterium pseudodiphtheriticum and Corynebacterium minutissimum strains as well as most (>70%) Corynebacterium jeikeium and Corynebacterium amycolatum strains. The most resistant organisms were Corynebacterium striatum and, to a lesser extent, Corynebacterium urealyticum. Resistance to erythromycin A was quite high, mainly in C. amycolatum, C. striatum, C. jeikeium and C. urealyticum.
The ketolide was active against all erythromycin A- Most erythromycin A-resistant strains (97.7%) were also resistant to both josamycin and lincomycin and only two strains (2.3%) were not resistant to josamycin but resistant to lincomycin.
The results obtained in this study confirm that many Corynebacterium spp. are resistant (57.9%) or nonsusceptible (intermediate and resistant) (79.6%) to erythromycin A. 5, 8 Only 24.3% of the strains were resistant to HMR 3004.
The pattern of susceptibility to erythromycin A, josamycin and lincomycin suggests that most macrolidelincomycin-ketolide resistance may result from target modification. In isolates that were macrolide-and ketolide-susceptible but lincomycin-resistant, drug inactivation may occur. It is interesting that HMR 3004 was active against 40 (46.5%) of 86 isolates resistant to erythromycin A, josamycin and lincomycin (target modification) and also active against two isolates (C. pseudodiphtheriticum and C. minutissimum) that were erythromycin A-and lincomycin-resistant but josamycinsensitive.
Macrolide-lincosamide-ketolide resistance in Grampositive organisms can be constitutively or inducibly expressed. 9 It has recently been shown that HMR 3004 displays good antibacterial activity against erythromycin A-inducibly resistant Gram-positive cocci and that ketolides are non-inducers of MLS B resistance, 10 so all these aspects merit attention in Corynebacterium spp.
